Can TCN2 rs1801198 mask subtle vitamin B12-related red-cell maturation strain despite normal serum B12 and methylmalonic acid?

Standard biochemical evaluations of vitamin B12 status rely heavily on total serum B12 and methylmalonic acid (MMA) levels. However, genetic variations in transport proteins can decouple circulating markers from intracellular availability, leaving tissue-level deficiencies undetected.

Mechanistic explanations

• The TCN2 rs1801198 (776C>G, Pro259Arg) polymorphism alters transcobalamin-mediated B12 delivery. The G allele (Arg259) consistently lowers circulating active holotranscobalamin (holo-TC) levels due to subtle conformational or stability changes that affect B12 loading efficiency or active transport half-life.
• Because holo-TC is the only fraction of vitamin B12 internalized by somatic cells via the CD320 cell-surface receptor, its depletion leads directly to intracellular deficiency.
• Total serum B12 remains largely unaffected in these carriers because the majority of circulating B12 is bound to metabolically inactive haptocorrin, masking intracellular starvation.

Clinical implications

• Inside the bone marrow, intracellular B12 deficiency impairs DNA synthesis in erythroid precursors, resulting in red-cell maturation strain.
• This maturation strain classically presents as elevated mean corpuscular volume (MCV) and higher red cell distribution width (RDW), even in the absence of overt, florid anemia.
• While MMA is a classic functional biomarker of B12 status, meta-analyses of the rs1801198 variant show inconsistent or null associations with MMA levels, meaning a normal MMA value cannot reliably rule out cellular-level deficiency in these patients.

Bottom line

• Normal serum B12 and MMA levels are insufficient to exclude intracellular B12 deficiency in TCN2 rs1801198 carriers, where elevated MCV and RDW can serve as early, subtle indicators of red-cell maturation strain.